It has been shown previously that alternative proteolytic processing is possible for endogenously expressed cathelicidin peptides, which may lead to different physiological effects in vivo 37. Therefore, it is likely that the immunological response under investigation will be altered depending on the concentration, location, cell types, and the form of mCRAMP

released during the response. BGB324 order The role of AMPs in regulating the magnitude of the adaptive immune antibody responses has not been investigated extensively and the results to date are contradictory. LL-37 (20 μg/mL) was shown to decrease IgM and IgG2a production from mouse splenic B cells activated with LPS and IFN-γ, primarily through inhibition of cell activation and proliferation 16. In contrast, another study demonstrated that LL-37 (6 μg/mL) increased the sensitivity of human peripheral B cells to CpG, enhancing B-cell activation and increasing IgM and IgG production 14. Our data using mCRAMP (100 ng/mL) and purified mouse B cells agree with the latter study 14 and show that mCRAMP increases the amount of IgG1 and IgE Luminespib chemical structure antibody production in Camp−/− B cells. Of course, two obvious differences that may account for the discrepancies seen are the use of LL-37 versus mCRAMP peptides and mouse versus human B cells. In addition, another very important variable to consider is AMP concentration. Since

it is nearly impossible to measure the physiological concentration within the splenic microenvironment where these responses are occurring, we titrated the mCRAMP concentration within our culture system ranging from 1 ng/mL to 10 μg/mL. DOCK10 Consistent with previous findings 38, our data showed that mCRAMP at the highest concentration

tested induced cell apoptosis, while moderate concentrations increased IgG1 production, and the lowest concentration showed no effect on IgG1 production. These observations suggest that the AMP concentration within the microenviroment of an immune response may partially dictate the positive or negative effect on antibody production. Our in vitro and in vivo data show that T cells exposed to mCRAMP produce less IL-4. However, the possibility exists that other cell types are affected by mCRAMP and secondarily affecting the T cells. LL-37 has been shown to drive mouse DC differentiation and enhance IL-6 and IL-12 production, while inhibiting IL-4 production. In addition, LL-37-exposed DCs increased IFN-γ production from T cells and polarize them to Th1 cells 39. Our in vitro data clearly show that mCRAMP is capable of acting directly on purified T cells that were polarized to Th2 cells and decrease their IL-4 production. Similarly, our in vivo data show that T cells produced more IL-4 in the absence of mCRAMP expression. IL-4 is the critical cytokine for the IgG1 class switch, and its elevated expression in the Camp−/− spleen after secondary i.p.